Signed in · PRO

Guidance history, every release

Incyte (INCY) · 8 releases, Oct 29, 2024 to Jul 28, 2026 · rows are metrics, columns are releases

Raised · a change from the previous releaseSame · restated unchanged— · not stated in that releaseEvery value links to its sentence in the filing

Metric	Oct 29, 2024 FY24 Q3	Feb 10, 2025 FY24 Q4	Apr 29, 2025 FY25 Q1	Jul 29, 2025 FY25 Q2	Oct 28, 2025 FY25 Q3	Feb 10, 2026 FY25 Q4	Apr 28, 2026 FY26 Q1	Jul 28, 2026 FY26 Q2
For FY2030
Goal for impactful product launches	—	New“more than 10”	—	—	—	—	—	—
High impact launches	—	—	New“more than 10”	—	—	—	—	—
For FY2026
Estimated impact on third and fourth quarters of 2026 net sales from improved GTN	—	—	—	—	—	—	—	New“$40 - $50 million”
Hematology and Oncology net product revenue (1)	—	—	—	—	—	New“$800 - $880 million”	—	—
Hematology and Oncology net sales	—	—	—	—	—	—	—	New“$860 - $890 million”
Hematology and Oncology net sales (3)	—	—	—	—	—	—	New“$800 - $880 million”	—
Jakafi net product revenue	—	—	—	—	—	New“$3,220 to $3,270 million”	—	—
Jakafi net sales (1)	—	—	—	—	—	—	New“$3,220 - $3,270 million”	—
Opzelura net product revenue	—	—	—	—	—	New“$750 to $790 million”	—	—
Opzelura net sales	—	—	—	—	—	—	—	New“$1,050 - $1,100 million”
Opzelura net sales (2)	—	—	—	—	—	—	New“$750 - $790 million”	—
Total estimated incremental impact on Opzelura net sales for the full year 2026	—	—	—	—	—	—	—	New“$300 - $310 million”
Total net product revenue	—	—	—	—	—	New“$4,770 to $4,940 million”	—	—
Total net sales	—	—	—	—	—	—	—	New“$5,130 - $5,260 million”
Total net sales	—	—	—	—	—	—	New“$4,770 - $4,940 million”	—
IPR&D expense	—	—	—	—	—	—	—	New“approximately $1,270 million”
IPR&D expense associated with Vega Therapeutics acquisition	—	—	—	—	—	—	—	New“approximately $1,270 million”
Total GAAP R&D and SG&A operating expense	—	—	—	—	—	New“$3,495 to $3,675 million”	—	Raised“$4,915 - $4,995 million”
Total GAAP R&D and SG&A operating expenses	—	—	—	—	—	—	New“$3,495 - $3,675 million”	—
Total non-GAAP R&D and SG&A operating expense	—	—	—	—	—	—	—	New“$4,625 - $4,695 million”
Total non-GAAP R&D and SG&A operating expenses (2)	—	—	—	—	—	New“$3,205 - $3,375 million”	—	—
Total Non-GAAP R&D and SG&A operating expenses (4)	—	—	—	—	—	—	New“$3,205 - $3,375 million”	—
For FY2025
GAAP Cost of product revenues	—	New“8.5% - 9.0% of net product revenues”	Reiterated“8.5% - 9.0% of net product revenues”	Widened“8.0% - 9.0% of net product revenues”	Reiterated“8.0% - 9.0% of net product revenues”	—	—	—
Jakafi net product revenue	—	—	—	—	New“$3.050 - $3.075 billion”	—	—	—
Jakafi net product revenues	—	—	—	New“$3,000 - $3,050 million”	Raised“$3,050 - $3,075 million”	—	—	—
Jakafi net product revenues (raised full year 2025)	—	—	New“$2,950 - $3,000 million”	—	—	—	—	—
Jakafi net revenues	—	New“$2,925 - $2,975 million”	—	—	—	—	—	—
Net product revenue	—	—	—	—	New“$4.23 - $4.32 billion”	—	—	—
Non-GAAP Cost of product revenues	—	New“7.5% - 8.0% of net product revenues”	Reiterated“7.5% - 8.0% of net product revenues”	Widened“7.0% - 8.0% of net product revenues”	—	—	—	—
Non-GAAP Cost of product revenues (2)	—	—	—	—	New“7.0% - 8.0% of net product revenues”	—	—	—
Opzelura ® (ruxolitinib) cream revenue	—	—	—	—	New“$630 - $670 million”	—	—	—
Opzelura net product revenues	—	—	New“$630 - $670 million”	—	Reiterated“$630 - $670 million”	—	—	—
Opzelura net revenues	—	New“$630 - $670 million”	—	—	—	—	—	—
Other hematology and oncology marketed products revenue	—	—	—	—	New“$550 - $575 million”	—	—	—
Other oncology net product revenues	—	New“$415 - $455 million”	Reiterated“$415 - $455 million”	Raised“$500 - $520 million”	—	—	—	—
Other oncology net product revenues (1)	—	—	—	—	New“$550 - $575 million”	—	—	—
GAAP Research and development expenses	—	New“$1,930 - $1,960 million”	Reiterated“$1,930 - $1,960 million”	Raised“$1,965 - $1,995 million”	Reiterated“$1,965 - $1,995 million”	—	—	—
GAAP Selling, general and administrative expenses	—	New“$1,280 - $1,310 million”	Reiterated“$1,280 - $1,310 million”	—	Reiterated“$1,280 - $1,310 million”	—	—	—
Jakafi	—	—	—	—	New“$3.050 - $3.075 billion”	—	—	—
Jakafi	—	—	—	New“$3,000 - $3,050 million”	—	—	—	—
Non-GAAP Research and development expenses	—	New“$1,780 - $1,805 million”	Reiterated“$1,780 - $1,805 million”	Raised“$1,815 - $1,840 million”	—	—	—	—
Non-GAAP Research and development expenses (3)	—	—	—	—	New“$1,815 - $1,840 million”	—	—	—
Non-GAAP Selling, general and administrative expenses	—	New“$1,160 - $1,185 million”	Reiterated“$1,160 - $1,185 million”	—	—	—	—	—
Non-GAAP Selling, general and administrative expenses (3)	—	—	—	—	New“$1,160 - $1,185 million”	—	—	—
Other Oncology	—	—	—	New“$500 - $520 million”	—	—	—	—
For FY2024
Jakafi net product revenues (raised)	New“$2,740 - $2,770 million”	—	—	—	—	—	—	—
Non-GAAP Cost of product revenues (2)	New“Unchanged”	—	—	—	—	—	—	—
Other Hematology/Oncology net product revenues (1)	New“$310 - $320 million”	—	—	—	—	—	—	—
GAAP Research and development expenses	New“$2,545 - $2,590 million”	—	—	—	—	—	—	—
Jakafi	New“$2,740 - $2,770 million”	—	—	—	—	—	—	—
Non-GAAP Research and development expenses (3)	New“$2,395 - $2,435 million”	—	—	—	—	—	—	—
Non-GAAP Selling, general and administrative expenses (3)	New“Unchanged”	—	—	—	—	—	—	—
Research and development one-time expenses included	New“$791 million”	—	—	—	—	—	—	—
No period stated
Incremental ongoing R&D investments related to the development of latarcibart	—	—	—	—	—	—	—	New“$50 million”

Values in quotation marks are the company’s words. Change labels compare each statement with the same metric and target year in the previous release. HighGravityData does not judge whether guidance was met.